Kiniksa Pharmaceuticals International PLC

The asset remains in a Stage 2 advance with a clear HH/HL structure and rising EMAs, supporting a bullish medium-term bias. A recent Bullish Exhaustion pattern at a marginal high triggered a pullback into the 9/20 EMA zone, offering a favorable entry on price support. Short-term momentum and trend context align, while overbought readings and moderate Stage 2→3 transition risk warrant cautious sizing and monitoring.

• ↑Q1 revenue $214.3M up 55.5% YoY; net income $22.6M vs $8.5M last year
• ↑Consensus Buy rating; avg target $62.71, Wedbush boosted to $72
• ↓Negative earnings yield indicates stock may be fully priced